Literature DB >> 6426381

In vitro antibacterial activity of cefpiramide.

M A Pfaller, A C Niles, P R Murray.   

Abstract

A microbroth dilution method was used to measure the MICs of cefpiramide (SM 1652), cefotaxime, moxalactam, ceftazidime, cefoperazone, ceftriaxone, piperacillin, and mezlocillin against 921 isolates of gram-negative (701) and gram-positive (220) bacteria. The activity of cefpiramide was equivalent to those of piperacillin and mezlocillin against members of the family Enterobacteriaceae and gram-positive isolates, including enterococci. Cefpiramide had equivalent or slightly greater activity against Pseudomonas aeruginosa than the other beta-lactam antibiotics tested.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6426381      PMCID: PMC185520          DOI: 10.1128/AAC.25.3.368

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  2 in total

1.  In vitro antibacterial activity of SM-1652, a new broad-spectrum cephalosporin with antipseudomonal activity.

Authors:  M Fukasawa; H Noguchi; T Okuda; T Komatsu; K Yano
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

2.  Antibacterial activities of SM-1652 compared with those of other broad-spectrum cephalosporins.

Authors:  M Kato; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

  2 in total
  7 in total

1.  High hepatic excretion in humans of cefpiramide, a new cephalosporin.

Authors:  J M Brogard; F Jehl; M Adloff; J F Blickle; H Monteil
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

2.  Pharmacokinetics and bacteriological efficacies of apalcillin and cefpiramide in experimental pneumococcal meningitis.

Authors:  K Sato; S Shelton; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

3.  Interpretive standards and quality control guidelines for cefpiramide disk susceptibility tests.

Authors:  A L Barry; T L Gavan; C Thornsberry; R N Jones
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

4.  Respiratory superinfections after the use of third-generation cephem antibiotics.

Authors:  A Saito; K Mori; Y Shigeno; K Yamaguchi; K Hara
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.

Authors:  N J Khan; J A Bihl; R F Schell; J L LeFrock; S J Weber
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

6.  Comparative in vitro activities of cefpiramide and apalcillin individually and in combination.

Authors:  J D Allan; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

7.  Comparative in vitro activity of cefpiramide, a new parenteral cephalosporin.

Authors:  C Quentin; P Noury; M Titonel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.